Alector, Inc. business relationships
Companies named in Alector, Inc.’s 10-K filed 2026-02-25, and public companies whose annual reports name Alector, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.9 / 10
- AI naming
- 23 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Alector, Inc.’s annual report 3
“In July 2021, we entered into a Collaboration and License Agreement with GSK, pursuant to which we and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including nivisnebart, which is currently in a Phase 2 trial, and latozinemab, for wh...” SEC filing
“We are developing, and if successful, plan to commercialize, nivisnebart with our partner GSK.” SEC filing
“The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.